Dexcom's Bet Beyond Diabetes
Share
Dexcom CEO Jake Leach joined Bloomberg Open Interest to explain why continuous glucose monitors are becoming much bigger than diabetes devices. He says GLP-1 drugs are actually boosting CGM adoption and defends the company's growth outlook. He also lays out Dexcom's push into mainstream metabolic health and wellness.
